{"product_id":"gastroschoum-reflusso-omeprazolo-20-mg-14-capsule-rigide","title":"Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules","description":"\u003cp\u003e\u003cstrong\u003eGastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules\u003c\/strong\u003e it's a \u003cstrong\u003eover-the-counter drug\u003c\/strong\u003e indicated for the treatment of \u003cstrong\u003egastric reflux symptoms\u003c\/strong\u003e in adults, as \u003cstrong\u003eheartburn\u003c\/strong\u003e e \u003cstrong\u003eacid regurgitation\u003c\/strong\u003e. Each hard capsule contains \u003cstrong\u003e20 mg omeprazole\u003c\/strong\u003e, active ingredient belonging to the category of \u003cstrong\u003eproton pump inhibitors (PPIs)\u003c\/strong\u003e, among the most used and clinically documented for \u003cstrong\u003ereduce the production of gastric acid\u003c\/strong\u003e and quickly alleviate ailments related to\u003cstrong\u003estomach acidity\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThanks to its targeted action on \u003cstrong\u003eproton pump\u003c\/strong\u003e, Gastroschoum Reflux works directly at the source of the problem: most patients get a \u003cstrong\u003eComplete relief from heartburn within 7 days\u003c\/strong\u003e with one \u003cstrong\u003esingle capsule per day\u003c\/strong\u003e, taken on an empty stomach at least 30 minutes before meals. The \u003cstrong\u003epack of 14 hard capsules\u003c\/strong\u003e it is ideal for a \u003cstrong\u003ecomplete two-week treatment cycle\u003c\/strong\u003e, practical to store and simple to take.\u003c\/p\u003e\n\u003cp\u003eGastroschoum Reflux \u003cstrong\u003eomeprazole 20 mg\u003c\/strong\u003e It is indicated for adults who suffer from \u003cstrong\u003egastroesophageal reflux\u003c\/strong\u003e, \u003cstrong\u003estomach acidity\u003c\/strong\u003e e \u003cstrong\u003eoccasional burning\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003eActive ingredients contained in Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules - What is the active ingredient in Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules?\u003c\/h3\u003e\nEach capsule contains \u003cstrong\u003e20 mg omeprazole\u003c\/strong\u003e. Excipients with known effects: each hard capsule contains \u003cstrong\u003e225 mg sodium\u003c\/strong\u003e. For the full list of excipients, see section 6.1.\n\n\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eEXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eComposition of Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules - What does Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules contain?\u003c\/h3\u003e\n\u003cb\u003e\u003ci\u003eCapsule contents:\u003c\/i\u003e\u003c\/b\u003e sodium hydrogen carbonate (E500ii), sodium starch glycolate (Type A), sodium stearyl fumarate (E485).\n\u003cb\u003e\u003ci\u003eCapsule:\u003c\/i\u003e\u003c\/b\u003e gelatine (E441), red iron oxide (E172), titanium dioxide (E171).\n\n\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eTherapeutic indications Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules - Why is Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules used? What is it for?\u003c\/h3\u003e\nGastroSchoum Reflux is indicated for \u003cstrong\u003etreatment of reflux symptoms\u003c\/strong\u003e (for example \u003cstrong\u003eheartburn\u003c\/strong\u003e, \u003cstrong\u003eacid regurgitation\u003c\/strong\u003e) in adults.\n\n\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eContraindications Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules - When should Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules not be used?\u003c\/h3\u003e\nHypersensitivity to omeprazole, substituted benzimidazoles or to any of the excipients listed in section 6.1. Omeprazole like others \u003cstrong\u003eproton pump inhibitors (PPIs)\u003c\/strong\u003e must not be used concomitantly with nelfinavir (see section 4.5).\n\n\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eQuantity and method of taking Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules - How is Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules taken?\u003c\/h3\u003e\n\u003cb\u003eAdults:\u003c\/b\u003e the recommended dose is \u003cstrong\u003e20 mg (one capsule) once a day for 14 days\u003c\/strong\u003e. You may need to take the capsules for 2-3 consecutive days to achieve improvement in symptoms. Most patients get a \u003cstrong\u003eComplete relief from heartburn within 7 days\u003c\/strong\u003e. Once complete disappearance of symptoms has been achieved, treatment should be discontinued.\n\u003cbr\u003e\u003cbr\u003e\n\u003cb\u003e\u003ci\u003eParticular populations.\u003c\/i\u003e\u003c\/b\u003e\n\u003cbr\u003e\n\u003cb\u003eRenal impairment:\u003c\/b\u003e no dosage adjustment is necessary in patients with impaired renal function (see section 5.2).\n\u003cbr\u003e\n\u003cb\u003eHepatic impairment:\u003c\/b\u003e patients with impaired liver function should consult a doctor before taking omeprazole (see section 5.2).\n\u003cbr\u003e\n\u003cb\u003eElderly:\u003c\/b\u003e no dose adjustment is necessary in elderly patients (see section 5.2).\n\u003cbr\u003e\n\u003cb\u003ePediatric population:\u003c\/b\u003e The use of GastroSchoum Reflux is not recommended for children and adolescents under \u003cstrong\u003e18 years of age\u003c\/strong\u003e.\n\u003cbr\u003e\u003cbr\u003e\n\u003ci\u003e\u003cu\u003eMethod of administration:\u003c\/u\u003e\u003c\/i\u003e GastroSchoum Reflux must be taken \u003cstrong\u003eon an empty stomach\u003c\/strong\u003e, at least \u003cstrong\u003e30 minutes before eating\u003c\/strong\u003e and at least two hours after the last meal. The capsule should be swallowed whole with half a glass of water and \u003cstrong\u003eit should not be chewed or opened\u003c\/strong\u003e.\n\n\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eStorage Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules - How is Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules stored?\u003c\/h3\u003e\nStore at \u003cstrong\u003etemperature below 25°C\u003c\/strong\u003e. Store in the original package in order to protect the medicine from moisture.\n\n\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWarnings Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules - On Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules it is important to know that:\u003c\/h3\u003e\nIn the presence of suspicious symptoms (e.g. significant and unwanted weight loss, recurrent vomiting, dysphagia, haematemesis or melena) and when gastric ulcer is suspected or present, the presence of a neoplasm should be excluded before instituting treatment.\n\u003cbr\u003e\u003cbr\u003e\n\u003cb\u003eClopidogrel:\u003c\/b\u003e as a precaution the concomitant use of omeprazole and clopidogrel should be avoided (see section 4.5).\n\u003cbr\u003e\u003cbr\u003e\n\u003cb\u003eSerious cutaneous adverse reactions (SCAR):\u003c\/b\u003e including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP), which may be life-threatening or fatal, have been reported very rarely in association with omeprazole treatment.\n\u003cbr\u003e\u003cbr\u003e\n\u003cb\u003eSubacute cutaneous lupus erythematosus (SLE):\u003c\/b\u003e Proton pump inhibitors are associated with extremely infrequent cases of SCLE. In the presence of skin lesions, especially on the parts exposed to sunlight, the patient must immediately contact a doctor.\n\u003cbr\u003e\u003cbr\u003e\n\u003cb\u003eRenal impairment:\u003c\/b\u003e Acute tubulointerstitial nephritis (TIN) has been observed in patients taking omeprazole. Omeprazole should be discontinued if TIN is suspected.\n\u003cbr\u003e\u003cbr\u003e\n\u003cb\u003eInterference with laboratory tests:\u003c\/b\u003e an increased level of Chromogranin A (CgA) can interfere with diagnostic tests for neuroendocrine tumors. Omeprazole treatment should be discontinued for at least 5 days before CgA measurements.\n\u003cbr\u003e\u003cbr\u003e\n\u003cb\u003eSodium:\u003c\/b\u003e this medicine contains \u003cstrong\u003e225 mg sodium per capsule\u003c\/strong\u003e, equivalent to 11.2% of the maximum daily amount of 2 g recommended by the WHO for an adult.\n\u003cbr\u003e\u003cbr\u003e\nPatients should be instructed to consult a doctor if: they have had a previous gastric ulcer or gastrointestinal surgery; have been on continuous symptomatic treatment for 4 or more weeks; have jaundice or severe liver disease; are over 55 years of age with new or recently changed symptoms.\n\n\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eInteractions Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules - Which medicines or foods can modify the effect of Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules?\u003c\/h3\u003e\n\u003cb\u003eNelfinavir, atazanavir:\u003c\/b\u003e the concomitant administration of omeprazole with nelfinavir is contraindicated. Co-administration with atazanavir is not recommended.\n\u003cbr\u003e\u003cbr\u003e\n\u003cb\u003eClopidogrel:\u003c\/b\u003e coadministration reduces exposure to the active metabolite of clopidogrel. As a precaution, concomitant use should be discouraged.\n\u003cbr\u003e\u003cbr\u003e\n\u003cb\u003eDigoxin:\u003c\/b\u003e Concomitant treatment with omeprazole may increase the bioavailability of digoxin. Therapeutic monitoring is recommended, especially in elderly patients at high doses.\n\u003cbr\u003e\u003cbr\u003e\n\u003cb\u003eSubstances metabolised by CYP2C19:\u003c\/b\u003e omeprazole is a moderate inhibitor of CYP2C19. The metabolism of substances such as R-warfarin, cilostazol, diazepam and phenytoin may be reduced with increased systemic exposure.\n\u003cbr\u003e\u003cbr\u003e\n\u003cb\u003eMethotrexate:\u003c\/b\u003e in the presence of high doses of methotrexate, it may be necessary to consider temporary discontinuation of omeprazole.\n\u003cbr\u003e\u003cbr\u003e\n\u003cb\u003eVoriconazole:\u003c\/b\u003e concomitant treatment leads to a more than two-fold increase in omeprazole exposure. Dose adjustment is generally not required.\n\n\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eSIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eLike all medicines, Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules can cause side effects - What are the side effects of Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules?\u003c\/h3\u003e\nThe most common side effects (1-10% of patients) are \u003cstrong\u003eheadache, abdominal pain, constipation, diarrhea, flatulence and nausea\/vomiting\u003c\/strong\u003e. Below is the complete classification by frequency according to MedDRA.\n\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eClassification by systems and organs\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cb\u003eFrequency\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cb\u003eAdverse Reaction\u003c\/b\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003ePathologies of the blood and lymphatic system\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eLeukopenia, thrombocytopenia\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003ePathologies of the blood and lymphatic system\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eVery rare\u003c\/td\u003e\n    \u003ctd\u003eAgranulocytosis, pancytopenia\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eImmune system disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eHypersensitivity reactions such as fever, angioedema, anaphylactic reaction\/shock\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eMetabolism and nutrition disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eHyponatremia\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eMetabolism and nutrition disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eNot known\u003c\/td\u003e\n    \u003ctd\u003eHypomagnesemia, hypocalcemia, hypokalemia\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003ePsychiatric disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eUncommon\u003c\/td\u003e\n    \u003ctd\u003eInsomnia\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003ePsychiatric disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eAgitation, confusion, depression\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003ePsychiatric disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eVery rare\u003c\/td\u003e\n    \u003ctd\u003eAggression, hallucinations\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eNervous system disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eMunicipality\u003c\/td\u003e\n    \u003ctd\u003eHeadache\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eNervous system disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eUncommon\u003c\/td\u003e\n    \u003ctd\u003eDizziness, paraesthesia, drowsiness\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eNervous system disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eTaste disorders\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eEye pathologies\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eBlurred vision\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eEar and labyrinth disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eUncommon\u003c\/td\u003e\n    \u003ctd\u003eDizziness\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eRespiratory, thoracic and mediastinal disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eBronchospasm\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eGastrointestinal disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eMunicipality\u003c\/td\u003e\n    \u003ctd\u003eAbdominal pain, constipation, diarrhea, flatulence, nausea\/vomiting, fundic gland polyps (benign)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eGastrointestinal disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eDry mouth, stomatitis, gastrointestinal candidiasis\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eGastrointestinal disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eNot known\u003c\/td\u003e\n    \u003ctd\u003eMicroscopic colitis\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eHepatobiliary disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eUncommon\u003c\/td\u003e\n    \u003ctd\u003eIncreased liver enzymes\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eHepatobiliary disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eHepatitis with or without jaundice\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eHepatobiliary disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eVery rare\u003c\/td\u003e\n    \u003ctd\u003eLiver failure, encephalopathy\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eUncommon\u003c\/td\u003e\n    \u003ctd\u003eDermatitis, pruritus, rash, urticaria\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eAlopecia, photosensitivity, AGEP, DRESS\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eVery rare\u003c\/td\u003e\n    \u003ctd\u003eErythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003ePathologies of the skin and subcutaneous tissue\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eNot known\u003c\/td\u003e\n    \u003ctd\u003eSubacute cutaneous lupus erythematosus (SLE)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003ePathologies of the musculoskeletal system\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eArthralgia, myalgia\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003ePathologies of the musculoskeletal system\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eVery rare\u003c\/td\u003e\n    \u003ctd\u003eMuscle weakness\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eRenal and urinary disorders\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eTubulointerstitial nephritis (with possible progression to renal failure)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003ePathologies of the reproductive system\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eVery rare\u003c\/td\u003e\n    \u003ctd\u003eGynecomastia\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eSystemic pathologies\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eUncommon\u003c\/td\u003e\n    \u003ctd\u003eMalaise, peripheral edema\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cb\u003eSystemic pathologies\u003c\/b\u003e\u003c\/td\u003e\n    \u003ctd\u003eRare\u003c\/td\u003e\n    \u003ctd\u003eIncreased sweating\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\n\u003cb\u003e\u003cu\u003eReporting of suspected adverse reactions.\u003c\/u\u003e\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\n\n\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eOVERDOSE\u003c\/h2\u003e\n\u003ch3\u003eOverdose Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules - What are the risks of Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules in case of overdose?\u003c\/h3\u003e\nData on overdose in humans are limited. Symptoms described include nausea, vomiting, dizziness, abdominal pain, diarrhea and headache. In case of overdose it is advisable to resort to symptomatic treatment by adopting generic support measures.\n\n\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eIf you are pregnant, think you may be pregnant or are planning to have a baby, or are breast-feeding, ask your doctor for advice before taking Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules\u003c\/h3\u003e\n\u003cb\u003ePregnancy:\u003c\/b\u003e The results of three prospective epidemiological studies (more than 1,000 exposed children) indicate that there are no adverse effects of omeprazole on pregnancy or on the health of the fetus\/newborn. Omeprazole can be used during pregnancy.\n\u003cbr\u003e\n\u003cb\u003eBreastfeeding:\u003c\/b\u003e Omeprazole is excreted in breast milk but is unlikely to affect the baby when used at therapeutic doses.\n\u003cbr\u003e\n\u003cb\u003eFertility:\u003c\/b\u003e Animal studies with orally administered omeprazole do not indicate effects on fertility.\n\n\u003cbr\u003e\u003cbr\u003e\n\u003ch2\u003eDRIVING AND USING MACHINERY\u003c\/h2\u003e\n\u003ch3\u003eTaking Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules before driving or using machinery - Does Gastroschoum Reflux Omeprazole 20 mg 14 Hard Capsules affect driving and using machinery?\u003c\/h3\u003e\nGastroSchoum Reflux has negligible effects on the ability to drive or use machines. However, in case of dizziness or visual disturbances, caution is recommended.","brand":"ZENTIVA ITALIA Srl","offers":[{"title":"Default Title","offer_id":54001922572615,"sku":"051151025","price":6.8,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/zentiva-italia-srl-gastroschoum-reflusso-omeprazolo-20-mg-14-capsule-rigide-farmacia-dottor-tili-1240520100.webp?v=1779809950","url":"https:\/\/www.dottortili.com\/en-eu\/products\/gastroschoum-reflux-omeprazole-20-mg-14-hard-capsules","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}